Managers / Q4 2024 · view latest →
BRIDGER MANAGEMENT, LLC
CIK 0001166309 · 90 PARK AVENUE, 40TH FLOOR, NEW YORK, NY, 10016 · 212-918-0820
Summary
Bridger Management, LLC reported $186M in U.S.-listed holdings across 28 positions for Q4 2024.
Its largest position, DWD, represents 12.7% of the portfolio.
Compared with Q3 2024, the fund opened 4 new positions and exited 5.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 83.9% · $156M
- ADR · 12.6% · $23M
- ETP · 3.5% · $7M
- Equity WRT · 0.0% · $9,987
Quarter-over-Quarter Changes full breakdown →
vs Q3 2024 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| ZBHZIMMER BIOMET HOLDINGS INC | NEW | +90.5K | 90.5K | +$10M | $10M |
| GMABGENMAB A/S | NEW | +291.5K | 291.5K | +$6M | $6M |
| MAMASTERCARD INCORPORATED | NEW | +2.4K | 2.4K | +$1M | $1M |
| HOODROBINHOOD MKTS INC | NEW | +26.7K | 26.7K | +$994,842 | $994,842 |
| OSCROSCAR HEALTH INC | SOLD OUT | −413.8K | 0 | −$9M | $0 |
| BMYBRISTOL-MYERS SQUIBB CO | SOLD OUT | −145.8K | 0 | −$8M | $0 |
| CN2CATALYST PHARMACEUTICALS INC | SOLD OUT | −90.7K | 0 | −$2M | $0 |
| YB4PSAVARA INC | SOLD OUT | −376.8K | 0 | −$2M | $0 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2024
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q1 2026 | $128M | 24 | May 15, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q4 2025 | $156M | 24 | Feb 17, 2026 | 13F-HR | changes · EDGAR ↗ |
| Q3 2025 | $186M | 28 | Nov 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q2 2025 | $170M | 25 | Aug 11, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q1 2025 | $201M | 29 | May 15, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q4 2024 | $186M | 28 | Feb 14, 2025 | 13F-HR | changes · EDGAR ↗ |
| Q3 2024 | $200M | 29 | Nov 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q2 2024 | $194M | 28 | Aug 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q1 2024 | $222M | 31 | May 15, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q4 2023 | $260M | 28 | Feb 14, 2024 | 13F-HR | changes · EDGAR ↗ |
| Q3 2023 | $272M | 31 | Nov 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q2 2023 | $300M | 29 | Aug 14, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q1 2023 | $268M | 28 | May 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q4 2022 | $247M | 23 | Feb 15, 2023 | 13F-HR | changes · EDGAR ↗ |
| Q3 2022 | $330M | 44 | Nov 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $444M | 43 | Aug 15, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $610M | 52 | May 13, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $773M | 44 | Feb 14, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $855M | 46 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $1.1B | 44 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $1.1B | 42 | May 14, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $1.3B | 39 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $1.3B | 36 | Nov 16, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $1.1B | 35 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $864M | 36 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $1.4B | 35 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $1.2B | 30 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $1.3B | 31 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $1.3B | 33 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $1.2B | 34 | Feb 14, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.